News
SRZN
31.85
+6.66%
1.99
Weekly Report: what happened at SRZN last week (0406-0410)?
Weekly Report · 1d ago
Weekly Report: what happened at SRZN last week (0330-0403)?
Weekly Report · 04/06 09:36
Surrozen announces annual stockholder meeting via webcast
Reuters · 04/01 20:25
SURROZEN INC: ENTERS SALES AGREEMENT TO SELL UP TO $50 MLN OF COMMON STOCK FROM TIME TO TIME - SEC FILING
Reuters · 03/31 10:14
Weekly Report: what happened at SRZN last week (0323-0327)?
Weekly Report · 03/30 09:36
LifeSci Capital Keeps Their Buy Rating on Surrozen (SRZN)
TipRanks · 03/28 14:36
TCG Crossover GP II reports Surrozen common share acquisition; value rises to $3,007,000
Reuters · 03/26 00:02
Guggenheim Keeps Their Buy Rating on Surrozen (SRZN)
TipRanks · 03/25 10:56
Surrozen Price Target Maintained With a $40.00/Share by Cantor Fitzgerald
Dow Jones · 03/24 13:38
Cantor Fitzgerald Sticks to Their Buy Rating for Surrozen (SRZN)
TipRanks · 03/24 11:36
Surrozen Price Target Raised to $36.00/Share From $32.00 by HC Wainwright & Co.
Dow Jones · 03/24 11:12
HC Wainwright & Co. Reiterates Buy on Surrozen, Raises Price Target to $36
Benzinga · 03/24 11:03
Surrozen price target raised to $36 from $32 at H.C. Wainwright
TipRanks · 03/24 10:15
SURROZEN, INC. <SRZN.O>: H.C. WAINWRIGHT RAISES TARGET PRICE TO $36 FROM $32
Reuters · 03/24 10:07
U.S. RESEARCH ROUNDUP-Apogee Therapeutics, Insmed, Sunoco
Reuters · 03/24 07:39
Analysts Are Bullish on Top Healthcare Stocks: CSL (CMXHF), Surrozen (SRZN)
TipRanks · 03/24 02:40
Surrozen Files Prospectus To Offer Up To $200M Of Securities
Benzinga · 03/23 21:39
Surrozen files $200M mixed securities shelf
TipRanks · 03/23 21:30
SURROZEN INC - MAY OFFER UP TO $200 MLN OF SECURITIES - SEC FILING
Reuters · 03/23 21:26
SURROZEN INC - MAY SELL UP TO $50 MLN OF COMMON STOCK UNDER SALES AGREEMENT WITH TD SECURITIES (USA) LLC - SEC FILING
Reuters · 03/23 21:26
More
Webull provides a variety of real-time SRZN stock news. You can receive the latest news about Surrozen Inc through multiple platforms. This information may help you make smarter investment decisions.
About SRZN
Surrozen, Inc. is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. The Company is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a focus in ophthalmology. Its product candidates include SZN-8141 for Retinal Diseases, SZN-8143 for Retinal Diseases, SZN-113 for Fuchs’ Endothelial Corneal Dystrophy and Geographic Atrophy, and SZN-413 for Retinal Diseases. SZN-8141 combines Frizzled 4 (Fzd4) agonism and Vascular Endothelial Growth Factor (VEGF) antagonism which has the potential to provide benefits over treatment with single agents for Diabetic Macular Edema (DME) and neovascular Age Related Macular Degeneration (wet AMD). SZN-8143 combines Fzd4 agonism, VEGF antagonism, and interleukin-6 (IL-6) antagonism which may have benefits over single agents for treatment of DME/wet AMD/uveitic macular edema. SZN-413 is a bi-specific antibody, designed using its SWAP technology.